Abbvie Inc.

Abbvie Deutschland Gmbh and Co Kg

Abbott Laboratories Corporation

Abbott Gmbh & Co Kg

Noel S Wilson

Michael M Friedman

Augustine Osuma

Anil Vasudevan

Justin D Dietrich

Eric C Breinlinger

Stevan Wakefield Djuric

Kristine E Frank

Kelly Mullen

Wilfried Martin Braje

Sean Colm Turner

Alan Frank Gasiecki

Irini Akritopoulou-Zanze

Michael Z Hoemann

Shashank Shekhar

Hongyu H Zhao

Ana-Lucia Relo

Min Zhang

Dennie S Welch

Albert Wayne Kruger

David Ihle

Jorge Gandarilla

Huanqiu Li

Christina M Thompson

Kenton L Longenecker

Lu Wang

Xiangdong Xu

Andrew Burchat

Phil B Cox

Gagandeep K Somal

J Martin Herold

David Andrew Kinsman

Philip Cox

Huan-Qui Li

Ann Marie Rowley

Raymond Huntley

Clara I Villamil

Arthur Gomtsyan

George S Sheppard

Jerome F Daanen

William J McClellan

Robert G Schmidt

David J Calderwood

Ramzi Farah Sweis

Yujia Dai

Michael Morytko

Maria A Argiriadi

Kevin Patrick Cusack

Bruce Clapham

Grier A Wallace

Dominique Bonafoux

Heather M Davis

Zhi Wang

Jennifer Van Camp

Bin Li

Stacy A Van Epps

Amanda W Dombrowski

Gloria Y LoSchiavo

Mike Michaelides

Hongyu Zhao

Shashank Shekar

The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions. 

Heterocyclic kinase inhibitors

The disclosure provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.

Indazolones as modulators of TNF signaling

The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.

Tricyclic modulators of TNF signaling

The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.

Indazolones as modulators of tnf signaling

The invention provides for compounds of formula (I) wherein R, R, R, R, R, and Rhave any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by SUV420H1. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Substituted indoles

The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I) wherein R, R, R, R, R, A, Y, Y, and Yare as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Modulators of 5-HT receptors and methods of use thereof

The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Primary carboxamides as BTK inhibitors

The present invention is directed to novel compounds of Formula (I) pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof wherein the variables are defined as herein. The compounds of Formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.

[object Object]

Growing community of inventors

Kenosha, WI, United States of America

Noel S Wilson